HALO
Price
$72.99
Change
+$1.32 (+1.84%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
8.43B
41 days until earnings call
Intraday BUY SELL Signals
SGMO
Price
$0.44
Change
-$0.01 (-2.22%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
150.88M
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HALO vs SGMO

Header iconHALO vs SGMO Comparison
Open Charts HALO vs SGMOBanner chart's image
Halozyme Therapeutics
Price$72.99
Change+$1.32 (+1.84%)
Volume$39.92K
Capitalization8.43B
Sangamo Therapeutics
Price$0.44
Change-$0.01 (-2.22%)
Volume$16.55K
Capitalization150.88M
HALO vs SGMO Comparison Chart in %
HALO
Daily Signal:
Gain/Loss:
SGMO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
HALO vs. SGMO commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a Hold and SGMO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (HALO: $71.67 vs. SGMO: $0.45)
Brand notoriety: HALO and SGMO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 44% vs. SGMO: 44%
Market capitalization -- HALO: $8.43B vs. SGMO: $150.88M
HALO [@Biotechnology] is valued at $8.43B. SGMO’s [@Biotechnology] market capitalization is $150.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $115.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 1 FA rating(s) are green whileSGMO’s FA Score has 0 green FA rating(s).

  • HALO’s FA Score: 1 green, 4 red.
  • SGMO’s FA Score: 0 green, 5 red.
According to our system of comparison, HALO is a better buy in the long-term than SGMO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 6 TA indicator(s) are bullish while SGMO’s TA Score has 4 bullish TA indicator(s).

  • HALO’s TA Score: 6 bullish, 4 bearish.
  • SGMO’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, both HALO and SGMO are a good buy in the short-term.

Price Growth

HALO (@Biotechnology) experienced а -2.00% price change this week, while SGMO (@Biotechnology) price change was +0.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

HALO is expected to report earnings on Feb 24, 2026.

SGMO is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HALO($8.43B) has a higher market cap than SGMO($151M). SGMO (6.762) and HALO (6.493) have similar YTD gains . HALO has higher annual earnings (EBITDA): 845M vs. SGMO (-101.17M). HALO has more cash in the bank: 702M vs. SGMO (29.6M). SGMO has less debt than HALO: SGMO (25.4M) vs HALO (1.51B). HALO has higher revenues than SGMO: HALO (1.24B) vs SGMO (32.9M).
HALOSGMOHALO / SGMO
Capitalization8.43B151M5,581%
EBITDA845M-101.17M-835%
Gain YTD6.4936.76296%
P/E Ratio15.12N/A-
Revenue1.24B32.9M3,778%
Total Cash702M29.6M2,372%
Total Debt1.51B25.4M5,949%
FUNDAMENTALS RATINGS
HALO vs SGMO: Fundamental Ratings
HALO
SGMO
OUTLOOK RATING
1..100
2710
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
45100
SMR RATING
1..100
12100
PRICE GROWTH RATING
1..100
4284
P/E GROWTH RATING
1..100
73100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SGMO's Valuation (65) in the Biotechnology industry is in the same range as HALO (75). This means that SGMO’s stock grew similarly to HALO’s over the last 12 months.

HALO's Profit vs Risk Rating (45) in the Biotechnology industry is somewhat better than the same rating for SGMO (100). This means that HALO’s stock grew somewhat faster than SGMO’s over the last 12 months.

HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for SGMO (100). This means that HALO’s stock grew significantly faster than SGMO’s over the last 12 months.

HALO's Price Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for SGMO (84). This means that HALO’s stock grew somewhat faster than SGMO’s over the last 12 months.

HALO's P/E Growth Rating (73) in the Biotechnology industry is in the same range as SGMO (100). This means that HALO’s stock grew similarly to SGMO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALOSGMO
RSI
ODDS (%)
Bearish Trend 3 days ago
65%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
Bullish Trend 8 days ago
73%
Declines
ODDS (%)
Bearish Trend 15 days ago
68%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
61%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
HALO
Daily Signal:
Gain/Loss:
SGMO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
QSMLX19.17-0.01
-0.05%
AQR Small Cap Multi-Style I
VIGIX252.87-0.61
-0.24%
Vanguard Growth Index Institutional
WMCVX9.59-0.04
-0.42%
Wasatch Small Cap Value
THGCX27.97-0.15
-0.53%
Thornburg International Equity C
NTKLX76.79-0.56
-0.72%
Voya Multi-Manager International Sm Cp A

HALO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HALO has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HALO
1D Price
Change %
HALO100%
-1.04%
AXON - HALO
47%
Loosely correlated
+1.55%
XENE - HALO
43%
Loosely correlated
-2.11%
SGMO - HALO
41%
Loosely correlated
-0.13%
TECH - HALO
35%
Loosely correlated
-0.30%
VCYT - HALO
34%
Loosely correlated
-0.92%
More

SGMO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SGMO has been loosely correlated with XENE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if SGMO jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SGMO
1D Price
Change %
SGMO100%
-0.13%
XENE - SGMO
54%
Loosely correlated
-2.11%
AXON - SGMO
51%
Loosely correlated
+1.55%
ARRY - SGMO
48%
Loosely correlated
-0.10%
BCRX - SGMO
46%
Loosely correlated
-4.80%
IDYA - SGMO
45%
Loosely correlated
-4.75%
More